<DOC>
	<DOCNO>NCT00605553</DOCNO>
	<brief_summary>This exploratory study evaluate SYN115 effect Parkinson 's disease measure clinical symptom brain image use magnetic resonance imaging ( MRI ) function test administer .</brief_summary>
	<brief_title>Study Evaluate SYN115 Parkinson 's Disease</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , two-way crossover study patient act control . Each patient enrol receive SYN115 ( 20 mg 60 mg ) placebo separate minimum one week washout period . An adaptive design use determine SYN115 elicit effect relevant PD few number patient perform interim analysis successive cohort patient receive 60 20 mg .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Diagnosis Parkinson 's disease Hoen Yahr stage 13 On stable dose antiparkinsons treatment 30 day prior screen Age 40 75 year Sign IRB approve informed consent Men woman agree use adequate birth control ECG measurement within normal limit Able understand study requirement Secondary Parkinson 's ( drug induce post stroke ) Received treatment investigational drug 30 day prior study entry Using disallow medication Significant neurological illness Parkinson 's IQ le 70 IQ test MMSE score &lt; = 23 History psychosis antipsychotic medication Current serious medical illness History substance abuse History head injury loss consciousness History brain surgery Contraindications MRI like claustrophobia , metal implant implantable device Abnormal liver function test and/or hepatitis cholangitis Gilberts disease Pregnant nursing Known hypersensitivity SYN115</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>